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Abstract 
Glucose variability (GV) is an integral component of glucose homeostasis although as 
yet not fully endorsed as an independent risk factor for long-term diabetic 
complications. However, it can represent the presence of excess glycaemic excursions 
and consequently the risk of hyper- or hypoglycaemia. At present GV is defined 
according to an ever increasing number of metrics representing either short- or longer-
term GV and is aimed at being incorporated into clinical practice. In the meantime, 
short-term within-day GV, with a coefficient of variation at 36% separates stable from 
labile glycaemic control. In contrast, longer-term GV is usually based on quarterly 
visit-to-visit measurements of HbA1c or other measures of glucose homeostasis. The 
relationship between GV and diabetes related complication predominantly from the 
recent literature is reported in this review along with reference to a number of non-
pharmacological and pharmacological strategies (GLP-1 receptor agonists, SGLT-2 
inhibitors, new long-acting insulins and also their fixed combinations with GLP-1 
receptor agonists), which are presently available to address this challenging aspect of 
diabetes management. 
 
Introduction 
Diabetes care management strategies from a “glucocentric” perspective should aim to 
address the three main components of dysglycaemia, i.e chronic hyperglycaemia, 
hypoglycaemia and glycaemic variability (GV).1 These features contribute to the 
development and progression of diabetic complications.2 Long-term interventional 
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trials comparing intensive with standard management of diabetes, have clearly 
demonstrated the association between prolonged poor glycaemic control and the 
development especially of microvascular and, to a lesser extent, macro-vascular 
complications.3,4. During the last decade, the deleterious effects of both short-term 
GV (within-day glucose fluctuations, peaks to nadirs), and long-term variations 
utilising fasting plasma glucose (FPG) and HbA1c have been proposed5,6 although 
definitive evidence on hard outcomes remains limited.7 It is now realised, however, 
that the availability of glucose monitoring, especially continuous glucose monitoring 
(CGM), is of considerable value for making management decisions, whereas on the 
other hand HbA1c used in isolation can be misleading.8 Short-term GV is of 
increasing concern for health care professionals intent on preventing excessive 
upward and downward fluctuations of glucose, with the potential risk of precipitating 
episodes of hyperglycaemia or hypoglycaemia respectively,6 with a negative impact 
on patients’ quality of life.9 Short or longer-term GV also appear to be associated with 
increased episodes of severe hypoglycaemia resulting in adverse cardiovascular 
outcomes and all-cause mortality.10,11  However, definitive evidence for the role of 
GV in the genesis and severity of chronic adverse clinical outcomes in persons with 
diabetes is still lacking compared to that of chronic glucose exposure, depicted by 
HbA1c.2–4  
Therefore, the aim of this article is primarily to review the relative large number of 
publications that have appeared during the last three years (2015 and onwards), but 
also to refer to the landmark studies published earlier, that address the issue of GV 
and diabetes complications. Clinically the relationship between GV and diabetes 
complications is presently not easy to establish due to heterogeneity between the 
studies including their design and especially the different metrics used to assess GV. 
Additionally, most antidiabetic treatments impact on components of the glycaemic 
‘triumvirate’ (ambient hyperglycaemia, GV and hypoglycaemia) to different 
degrees.1, 12–16 Individualising care (‘precision’ medicine) based on daily continuous 
glucose profiles and GV is the eventual glycaemic objective. However, it should be 
acknowledged that such an objective might take a long time. 
 
Literature search strategy 
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• Literature searches were completed for the terms “glycaemic variability”, 
“glucose variability”, “fasting glucose variability”, “HbA1c variability”, 
“glucose fluctuation” and “oscillating glucose”. Database used was PubMed. 
• References retrieved were reviewed and selected manually according to their 
relevance to the aims of this review. Except for the key historical references 
on the topic, priority for inclusion has been given to relevant literature 
published in the last 3 years (2015 and onwards). 
 
Metrics of glycaemic variability: does profusion create confusion? 
GV is usually defined by the measurement of fluctuations of glucose or other related 
parameters of glucose homeostasis over a given interval of time. This description 
covers two predominant categories of measurements (Table 1): (a) “short-term” GV 
represented by both within-and between-day GV and (b)  “long-term” GV based on 
serial determinations over a longer period of time, usually involving HbA1c, but also 
serial FPG and postprandial glucose (PPG) measurements. However, the acceptance 
and clinical relevance of this proposed classification remains a subject of debate. For 
many years, short-term GV was calculated from self-monitoring of blood glucose 
(SMBG) measurements7, but this method is being progressively replaced during the 
last past few years by continuous glucose monitoring (CGM).17,18 SMBG at best 
provides an abbreviated diurnal blood glucose profile19 whereas CGM with interstitial 
glucose measurements at 5 minutes-time intervals is a more comprehensive record 
covering the day and night time periods and regarded as the gold standard method for 
assessing short-term GV.17,18 Fleisher and colleagues also recently reported a poor 
correlation (R2 = 0·26, p< 0·05) between the mean amplitude of glycaemic excursion 
(MAGE) obtained from structured SMBG testing and those computed from CGM.19 
However, structured SMBG provides the possibility to determine the two main 
components of short-term GV ie: the “within- and between-day” GV. Traditional 
measures of within-day GV include either or both the standard deviation (SD) and 
derived coefficient of variation (CV). When averaging each daily SD or CV the 
“mean of within-day daily” GV over the stated period of time can also be estimated.20 
Another method is to calculate the SD from the averaged glucose profiles, which is 
called the “daily SD by average”. This estimate is usually smaller than the “mean of 
within-day daily SD”, with the underestimation exaggerated when the glucose 
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patterns from day-to-day becomes more different. A large disparity between these two 
indices reflects a high degree of between-day GV.21  
The metrics considered the best for estimating the between-day GV is the MODD 
(Mean Of Daily Differences)21 which was introduced in the early 1970’s by Molnar 
and colleagues.22 The computation is based on the calculation of the absolute 
differences between two glucose values measured at the same time within a 24-h 
interval with a high MODD score indicative of a large between-day GV. This metrics 
is not currently provided with the available CGM devices thus requiring additional 
computation. 
An additional parameter of GV is the dispersion of the glucose data at given time-
points over several consecutive days employed by the Flash monitoring system the 
Free Style Libre, which computes the “Averaged Glycaemic Profile” over a defined 
period of 14 days with the results reported as Interquartile Ranges (IQRs).23 A high 
IQRs indicates a loss of synchrony of glucose patterns from day-to-day, i.e. a high 
between-day GV whereas a low IQRs implies little between-day GV.20,21 
Other more complex metrics are also available for assessing short-term GV, but are 
rarely applied in routine clinical practice and are reported in the Table 1.  
 Although we have mainly focused on the metrics of GV based on the SD, whilst 
omitting the more complicated computations, the output can still remain somewhat 
difficult to interpret. Therefore, simplifying the message is a prerequisite for 
healthcare providers to easily calculate and interpret short-term GV. We recently 
proposed the coefficient of variation (CV) as the most appropriate index for assessing 
mean within-day daily GV and which is independent of the mean glucose 
concentration with a cut-off threshold value of 36% separating stable from labile 
glycaemic control.6 Although the attributed level of evidence for this threshold has 
been graded as E (Expert consensus of clinical evidence using the grading system 
developed by the ADA), it has recently been adopted by the International consensus 
on the use of continuous glucose monitoring [18]. A few years earlier based on 
personal observations a threshold value equivalent to a CV of 33% was suggested by 
Hirsch [24] as an ideal target derived using the following formula: SD x 3/ mean 
glucose. Some experts express the difficulty in defining a meaningful threshold for 
short-term GV in order to differentiate labile from stable diabetes. However, it should 
be remembered the difficulties encountered in arriving at clear recommendations for 
HbA1c that separate satisfactory from unsatisfactory diabetes control and for the 
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definition of hypoglycaemia [25]. As described in our original publication we chose 
to consider as a reference for stable diabetes a group of persons treated only with 
dietary measures and/or insulin sensitizers, with a minimal risk of hypoglycaemia, 
and defined the threshold between stable and unstable diabetes as the upper limit of 
the distribution of CV in this group.  
The second type of GV, namely long-term GV, is usually based on visit-to-visit 
measurements of HbA1c, FPG or PPG,26 with the subsequent calculation of their SD 
and CV. The long-term GV is in part a reflection of the ambient hyperglycaemia 
because measures of long-term variability correlate with either mean blood glucose 
concentrations (r = 0·73)7 or mean HbA1c (r = 0·55).27 As mentioned by others it is 
highly likely that this definition of long term variability is an umbrella term that 
encompasses different concepts and definitions [28 Noyes et al Diabetic Medicine 
2018;36:262-269  NOTE a new reference] 
The current lack of consensus on the metrics to describe both short-term and long-
term GV partly contributes to difficulties in establishing the relationships between 
them and clinical outcomes.   
Table 1 attempts to represent a simplified view of the different metrics of GV 
available, summarising their outcomes (interpretation), advantages and limitations. 
 
Mechanisms 
Two historical in vitro studies showed that short-term (4 days) and longer-term (21 
days) glucose oscillation enhanced human tubule-interstitial cell growth and collagen 
synthesis29 and accelerated apotosis in human umbilical vein endothelial cells 30 more 
than exposure to a constantly high glucose level. Shortly afterwards, it was shown that 
oxidative stress was the key player in producing damage to endothelial cells.31 Several 
other studies have since confirmed that oscillating glucose, via oxidative stress, can 
adversely affects cells of different organs.32 More recently the source and the targets 
of oxidative stress during glucose fluctuation have been further characterized. The 
mitochondrion is still considered the key player in inducing superoxide production 
during GV, together with NADPH oxidase.33,34 Most recently, the involvement of the 
AKT pathway in this process has also been recognised.35  Blood glucose fluctuation 
accelerates renal injury involving inhibition of the AKT signalling pathway in 
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diabetic rats.36 GV can also induce increased chromatin remodelling37 which, can play 
an important role in GV- induced “metabolic memory”.38   
Human’s studies are less consistent with some showing that oxidative stress is 
produced during GV 1,39 and that oscillating glucose is more deleterious to endothelial 
function via oxidative stress than mean glucose in subjects with or without and type 2 
diabetes (T2D).40 Other studies were unable to confirm that short-term GV was 
associated with raised oxidative stress markers in healthy volunteer41,42 and type 1 
diabetes (T1D).42 As insulin has an inhibitory action on inflammation, thrombosis and 
activation of oxidative stress, the possibility that insulin affected the results, in 
positive or negative way, cannot be excluded. 
Intriguingly, it has been recently reported that in T2D in remission after bariatric 
surgery, there is an increased GV, which is accompanied by an increase in oxidative 
stress.43 
Evidence also exists that hyperglycaemia after recovery from hypoglycaemia worsens 
endothelial function and increases oxidative stress and inflammation in healthy 
control subjects and subjects with T1D. This does not appear when recovery from 
hypoglycaemia is followed by normoglycaemia.44
 
 
Glucose variability: hard outcomes in persons with and without diabetes 
Pre-2015 several studies have reported a positive association between GV and 
diabetic complications, both macro- and micro-vascular.32 In the last three years new 
evidence has appeared in support of GV being an independent risk factor for total 
mortality and death due to cardiovascular disease in both T1D and T2D.26, 45–49 
GV increased recurrent cardiovascular events and mortality in persons with diabetes 
following episodes of acute ischemic stroke.50 An elevated GV is significantly 
associated with 3-month cardiovascular composite outcome, with increased 
cardiovascular outcomes in the highest GV quartile similar in both euglycaemic and 
hyperglycaemic groups. Moreover, a very recent study reported a strong association 
between long term GV and mortality in old patients with diabetes.51 It is of 
considerable interest that within day GV evaluated by CGMS is associated with the 
10-year cardiovascular risk in well-controlled diabetic patients based on HbA1c.52 
These data are consistent with the evidence that indicate short-term GV may 
adversely affect diabetes plaque stability,53 subclinical coronary atherosclerosis54 and 
extends QTc duration and dispersion.55 More recently, longer-term HbA1c variability 
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has been associated with a higher risk of developing atrial fibrillation56 and the 
incidence of heart failure.57 Moreover, reducing GV with insulin via continuous 
subcutaneous infusion is accompanied by an increase in circulating endothelial 
progenitor cells in T1D.58  
Similarly, long-term GV (HbA1c) in T2D has been associated with the risk of 
developing diabetic nephropathy.59,60  
Also an association between long-term GV (HbA1c) and diabetic retinopathy has 
been demonstrated in some studies with T1D.61,62 GV causes inner retinal sensory 
neuropathy in persons with T1D.63 However, no association was seen between short- 
or long-term GV with progression of microvascular outcomes in T1D in the Diabetes 
Control and Complications Trial.7 
GV seems also to be a risk factor for diabetic neuropathy, and not only in terms of 
retinal neurodegeneration,61 but particularly in terms of polyneuropathy and 
cardiovascular autonomic neuropathy in persons with T2D.64,65 A reduced cardiac 
autonomic modulation is evident in women with T2D with high GV.66 
There is also considerable interest for the emerging association between GV and the 
decline of cognitive function.67,68 HbA1c variability appears to predict symptoms of 
depression in elderly individuals with T2D,69 including the risk of developing the 
Alzheimer disease.70 It has also been suggested that repetitive GV at brain level may 
produce “relative cerebral hypoglycaemia”,71 which can induce neuroglycopenia with 
further impairment of cerebral blood flow, paving the way for a recurring pattern of 
hypoglycaemia, hypoglycaemia unawareness, and associated neuropathology with 
cognitive dysfunction. 
As anticipated, even cumulative evidence suggest a role for GV in diabetic 
complications, there are also studies to the contrary. Recently, a post-hoc analysis 
from the DCCT assessed the association of GV within and between quarterly 7-point 
glucose profiles with the development and progression of retinopathy, nephropathy, 
and cardiovascular autonomic neuropathy.7 Measures of variability included the 
within-day and updated mean (over time) of the SD, MAGE, and M-value, and the 
longitudinal within-day, between-day, and total variances. Adjusted for mean blood 
glucose, no measure of within-day variability was associated with any adverse 
outcome.  
When GV has been evaluated as risk factor for complications in the DCCT the results 
have been predominantly negative, but also inconsistent with HbA1c variability 
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associated with increased risk of retinopathy.72 Limitations of the current studies, as 
underlined by the same authors of the DCCT, include a reliance on seven-point 
SMBG profiles at quarterly intervals to represent the mean blood glucose 
concentrations and variability over time.73 Such infrequent measurements can 
therefore lead to erroneous measures of GV.73  
An interesting aspect of GV is its impact in people without diabetes. GV is an 
independent risk factor for a worse outcome in several acute conditions74 although 
when corrected for other confounding variables this association can be lost.75 
However, a meta-analysis indicated that GV remains a risk factor even when 
correcting for several confounding variables: (severity of illness expressed as 
APACHE II score), the overall blood glucose level (expressed as the mean blood 
glucose of the entire stay of the patient in the intensive care unit [ICU]); blood 
glucose measurement frequency (expressed as the mean interval between 
measurements); having at least one severe hypoglycaemia event (< 40 mg/dl blood 
glucose level).76  
GV also seems to indicate an increased risk of a major cardiovascular event after 30 
days following acute coronary syndrome,77 isolated cardiac valvular surgery78 and 
intracerebral haemorrhage.79 More recently, GV has also been associated with higher 
risk of mortality in the general population.80  
Interestingly, increased GV has been found to be strongly associated with mortality in 
ICU in persons without diabetes, but less so in those with diabetes.81 Similarly, a 
poorer 30-day functional outcome following acute intracerebral hemorrhage was 
observed in those without diabetes and increased GV.79 
In those persons with an HbA1c > 8·5%, increasing GV was not associated with 
increased mortality.82 Hypoglycaemia was also associated with mortality, but prior 
exposure to hyperglycaemia had a lesser effect on this relationship. As a hypothesis, 
previous exposure to hyperglycaemia may act as a “preconditioning” factor, 
minimizing the effect of GV. 
It should be acknowledged that at present we are sadly lacking of any long-term 
interventional study providing compelling evidence for a beneficial effect of reduction 
in short-term GV on hard outcomes such as the development and progression of 
micro- and macro-vascular diseases. Firstly, in all studies aimed at attenuating the 
magnitude of GV or of postprandial excursions, the tested group and its comparator 
were submitted to pharmacological interventions using different treatment regimens 
 10 
but always with at least one insulin preparation in both groups. For instance, the Heart 
2D Study83, was initially designed to answer whether control of basal or prandial 
hyperglycaemia is best for reducing cardiovascular outcomes in poorly controlled 
T2D. Patients were assigned to either a basal insulin strategy or an insulin regimen 
with 3 daily injections of rapid insulin-acting analogues at pre-meal times. Therefore, 
it appears that both groups were treated with insulin. At the end of the study, almost 
all people were anyhow treated with both basal and prandial insulin and, even 
statistically significant, the difference in postprandial hyperglycaemia during the 
study was not that predefined in the study.83 Interestingly, in a post-hoc analysis a 
beneficial effect on reducing post-prandial hyperglycaemia was reported in oldest 
people and in people with a longer duration of the disease.84  
The same remark can be applied to the FLAT-SUGAR study13 that was designed to 
test whether an add-on therapy with exenatide to an on-going basal insulin regimen 
can reduce short-term GV and improve cardio-metabolic risk markers. The 
albuminuria, serum C reactive protein, serum interleukin-6 and urinary prostaglandin 
F2ά, were also similar in the two treatment strategies. The difference in GV was 
relatively small and the duration of the study was very short and both groups were on 
insulin treatment. Insulin has an inhibitory action on inflammation, thrombosis and 
activation of oxidative stress,85 and therefore one can hypothesise that the potential 
benefit of reducing GV or postprandial excursions may not be apparent due to the 
predominant response to insulin per se. The second difficulty lies in the fact that most 
antidiabetic therapies exert their effects on diabetic control via a concomitant 
reduction in both ambient hyperglycaemia and GV13. As a consequence, the ideal 
randomized intervention trial for testing the specific impact of reducing GV on 
cardio-metabolic risk markers and beyond (hard cardiovascular outcomes) should 
avoid the use of insulin treatment in the comparator groups86 and aim to achieve a 
similar degree of ambient hyperglycaemia in those with or without improvement in 
GV. Finally, one can anticipate difficulty in conducting a study with CGM over a 
prolonged period of time unless suitable wearable devices became available. 
According to these remarks it is questionable whether such trials are technically, 
financially and ethically feasible. For all these reasons, in vitro experiments on cells 
or in vivo experimental studies in animals and humans therefore provide at present the 
best opportunity for investigating the potential deleterious role of abnormally high 
GV despite the many obvious limitations.  
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Relationship between glycaemic variability and hypoglycaemia 
Achieving near normoglycaemia is a key objective in the management of diabetes, 
which is well supported by observational, epidemiologic and several interventional 
studies confirming the relationship with cardiovascular events, premature death and 
microvascular complications.87 
Unfortunately, the maintenance of normoglycaemia over a lifetime of diabetes is a 
major challenge whilst also attempting to avoid hypoglycaemia.88 In 2000, the authors 
of the Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) 
demonstrated that striving to achieve a too stringent glycaemic goal (HbA1c < 6%, 42 
mmol/mol) with intensive therapy resulted in increased frequency of hypoglycaemia 
although not causally related to increased risk of cardiac death.89 Therefore, the 
principle should be to achieve the best glycaemic control whilst limiting the risk of 
hypoglycaemia. Such a strategy will, however, increase the risk for the development 
or progression of micro-angiopathic complications, especially when applied to 
younger patients with a long life expectancy. It is also important to be aware that 
excessive short-term GV, even in the presence of target HbA1c levels, can contribute 
to the risk of hypoglycaemia. This risk is more likely when the mean blood glucose is 
low or if deviations around the mean glucose values are large,90 advocating the need 
to reduce short-term GV. The role of acute glucose fluctuations as a risk factor for 
hypoglycaemia has only recently been fully demonstrated using CGM technology. In 
persons with T2D treated with either oral antidiabetic and/or insulin, the mean 
glucose concentration and its SD were the best variables at predicting the frequency 
of asymptomatic hypoglycaemia.91 Incident asymptomatic hypoglycaemia (interstitial 
glucose value < 3·3 mmol/L, 56 mg/dL) was negatively associated with the mean 
glucose concentration but positively associated with short-term GV as represented by 
the SD.91 Similar findings were observed when analysing 828 day-patient glycaemic 
profiles (ambulatory CGM) carried out in T1D (331), T2D treated with insulin (216) 
and  non-insulin-treated T2D (222).92 The three groups were further divided into three 
subgroups according to whether the 24-hour mean glucose value was < 8·3 mmol/L 
(<150 mg/dL), between 8·3–10·0 mmol/L (150 and 180 mg/dL)  or > 10 mmol/L 
(>180 mg/ dL). Finally, in each subset, the frequency of hypoglycaemic episodes 
(interstitial glucose values < 3·3 mmol/L, 56 mg/dL) was compared according to 
whether the within-day GV (SD around the mean glucose value) was above or below 
 12 
the mean SD in each selected subgroup which was 3·3 mmol/L (60 mg/dL) in T1D, 
2·9 mmol/L (50 mg/dL) in insulin-treated T2D and 1·7 mmol/L (30 mg/dL) in non-
insulin-treated subjects (Figure 1). The frequency of hypoglycaemic episodes when 
ranked according to decreasing ordinal were T1D> insulin-treated T2D> non-insulin-
treated T2D and also within each category of diabetes, the frequency of 
hypoglycaemic episodes increased with decreasing mean glucose values. Importantly, 
in each subgroup, the frequency of hypoglycaemic episodes increased substantially 
when the GV exceeded the mean SD value and representing an increased risk for 
hypoglycaemia.  In a similar group of subjects it has been also demonstrated that the 
incidence of hypoglycaemic events is 3 to 6-fold greater in those with a within-day 
CV> 36% (referred to as labile diabetes) than in a subgroup with a CV ≤36% 
(considered to be stable) irrespective of the type of diabetes either T2D treated with 
oral antidiabetic agents including a sulfonylurea, T2D on insulin or T1D.6 The mean 
glucose concentrations were similar across the three groups, confirming that the 
within-day GV is a key player associated with the incidence of hypoglycaemia.  
An additional pending question is to know whether excessive acute glucose 
fluctuations can exert adverse effects independently of hypoglycaemia. Oxidative 
stress has been observed in poorly controlled T2D patients (HbA1c levels 9·6%) with 
acute glucose fluctuations who did not suffer from any hypoglycaemic events.39 
 
Glycaemic variability and therapeutic implications 
Glucose variability treatment: non-pharmacological options  
The HypoCOMPaSS trial suggested a role for education in decreasing GV in subjects 
with long-lasting T1D with frequent severe hypoglycaemia and the presence of 
hypoglycaemia unawareness.93 Moderate physical exercise has been shown to lower 
GV and reduce oxidative stress in subjects with T2D and impaired glucose 
tolerance.94  
Combining CGM with appropriate education appears a promising strategy for 
improving glycaemic control.16 In the DIAMOND trial16 the authors found that 
persons with T1D using CGM compared with usual care resulted in an improvement 
in both HbA1c (- 0·6%) and GV (CV- 4%) from a similar baseline value of 42%. 
A recent review reported that CGM has beneficial effects on metabolic control 
(reduced risk of hypo- and hyperglycaemia, decreased GV, mean glucose, and HbA1c 
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values) in both T1D and T2D undertaking various treatment regimens (either multiple 
daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII)).95 
Glucose variability treatment: pharmacological options 
Achieving a normal or near-normal HbA1c value without increasing the risk of 
hypoglycaemia is crucial especially during the early stages of T2D with a HbA1c 
between 6·5 and 7·5% (47 and 58 mmol/mol) respectively, when dysglycaemia is 
limited to an exaggerated dawn phenomenon and/or abnormal postprandial 
excursions.96 A post-hoc analysis of the OPTIMA study using CGM showed that the 
dipeptidyl-peptidase 4 inhibitor (DPP-4i) agents sitagliptin and vildagliptin, when 
prescribed as add-on therapy to metformin in persons with T2D, achieved a reduction 
of GV (MAGE).96 A similar effect may be obtained with the sodium-glucose 
cotransporter 2 inhibitors (SGLT-2i) in T1D.97,98 
When oral antidiabetic agents fail to achieve or maintain satisfactory glycaemic 
control, it is necessary to advance towards injectable antidiabetic therapies, the 
options being between adding a basal insulin or a GLP-1 receptor agonist (GLP-
1RA).99 The addition of exenatide once weekly to metformin in T2D subjects 
improves glucose control with a significant decrease in FPG, 2h-PPG and GV 
(MAGE and SD of mean glucose) and increasing the time spent in euglycaemia and 
less in hypoglycaemia.100 Similarly, lixisenatide when added to basal insulin therapy 
significantly decreases the risk of hypoglycaemia and GV.101 When comparing insulin 
glargine U100 (IGlar100) with insulin glargine U300 (IGlar300) in T2D, there is no 
significant change in short term GV except for MODD being lower with  IGlar100.102  
In the DEVOTE trial the cardiovascular safety of insulin degludec (IDeg) was 
compared to IGlar100 in T2D subjects at high cardiovascular risk.12 The study 
demonstrated that IDeg in comparison to IGlar100 at equivalent levels of glycaemic 
control, lowered episodes of confirmed severe hypoglycaemia by 40% and nocturnal 
severe hypoglycaemia by 53%. In addition, in a post-hoc analysis of this trial 
(DEVOTE 2) it was found that a positive correlation existed between the inter-day 
FPG variability and both the risk of severe hypoglycaemia and all-cause mortality.10 
When the basal insulin supplementation is deemed insufficient in T2D two further 
options are currently available, include the addition of a GLP-1RA or a short-acting 
insulin analogue. There are two randomized studies, the FLAT-SUGAR Trial,13 and 
the AWARD-4 substudy,14   which have assessed the impact of basal insulin in 
combination with a GLP-1RA on both the ambient hyperglycaemia and GV. The 
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FLAT-SUGAR trial was a 26-week randomized trial comparing a basal-bolus insulin 
regimen to basal-insulin with the short-acting GLP-1RA exenatide, injected twice 
daily before the largest meals.  This therapeutic strategy resulted in a reduced short-
term GV (CV and MAGE) although the improvement in HbA1c was equivalent in the 
two therapeutic groups.  
The AWARD-4 sub-study14 in persons with T2D conducted over an initial period of 
26 weeks and extended to 52 weeks found that the between-day GV (MODD) was 
slightly but significantly decreased with the once daily GLP-1RA dulaglutide plus 
prandial insulin lispro when compared to a basal-bolus insulin regimen of IGlar100 
plus prandial lispro. More recently, however, improvements in both ambient 
hyperglycaemia (% participants within glucose target range 3·9 to 9·0 mmol/L), GV 
and lowering the risk of hypoglycaemia has been observed when a fixed ratio 
combination of basal IDeg and the GLP-1RA liraglutide (IDegLira) was compared to 
either IDeg or liraglutide administered alone.103  
In summary, it appears clearly that in the management of T2D the incretin-based 
therapies either incretin-modulators (DPP-4i) at an early stage of the disease or 
incretin-mimetics (GLP-1RA) at a later stage can reduce concomitantly the ambient 
hyperglycaemia and the GV without enhancing the risk of hypoglycaemia. 
The recent addition of the ultra-long acting insulin preparations can also lower GV, 
with a reduced risk of hypoglycaemia and providing greater flexibility in dose 
administration whilst maintaining overall efficacy remains.104   
 
Conclusions 
With the adoption of blood glucose monitoring, made easier and more meaningful by 
the availability of CGM, GV is emerging as an additional glycaemic target, even 
though doubt remains over its role either as short- or long-term GV as independent 
risk factors for diabetes related complications. The enhanced risk appears related both 
to the possible vascular damage due to excessive glucose fluctuations and the 
increased risk of hypoglycaemia and its consequences. Providing health care 
professionals with such information on GV needs to be limited to indices which can 
be easily obtained and interpreted, coupled with an awareness of the different lifestyle 
and therapeutic options available to lower GV safely and without compromising 
glycaemic control. Currently, limiting the assessment of within-day GV based on the 
magnitude of the SD and/or the derived CV should limit confusion. It is noteworthy 
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that the International Consensus of Use of Continuous Glucose Monitoring has 
recently integrated a CV < 36% as a key metrics of primary GV for defining stable 
diabetes.18   Further recent developments of clinical value with CGM includes the 
Flash monitoring system of Free Style Libre. Future developments in CGM systems 
and indices for better defining and deciphering glycaemic control including GV and 
relevance to clinical practice are eagerly awaited in this fast moving and essential 
segment of diabetes management. 
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Figure 1: Total (symptomatic plus asymptomatic) hypoglycaemic episodes (interstitial 
glucose concentration< 56 mg/dL) during continuous glucose monitoring expressed as 
number/patient-day in 3 groups of persons with T1D (figure 1a), T2D treated with 
insulin (figure 1b) and T2D treated only with diet and oral antidiabetic agents (figure 
1c); (Adapted from Monnier, L, Colette, C, Dejager, S, and Owens, DR. Near normal 
HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. 
Rev Endocr Metab Disord. 2016; 17: 91–101).  
Table 1: List of main metrics developed for assessing glycemic variability. For each 
index, short notes on computation, interpretation, advantages and limitations are 
indicated. 
Glossary: 
SD = standard deviation 
CV = coefficient of variation 
MAGE = Mean Amplitude of Glycemic Excursions 
CONGA = Continuous Overlapping Net Glycemic Acting 
ADRR = Average Daily Risk Range 
LBGI = Low Blood Glucose Index 
HBGI = High Blood Glucose Index 
MAG = Mean Absolute Glucose Variation 
IQR = Interquartile Range, i.e. dispersion of data between the 25th and 75th percentile 
around the median 
AGP = Averaged Glycemic Profile over several consecutive days (14 days with the 
Free Style Libre) 
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